Proposed Project: Program Data Report Form for the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act of 1990, Title III HIV Early Intervention Services Program

(OMB No. 0915–0158)—Revision and Extension—Title III of the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act of 1990, as amended by the CARE Act Amendments of 1996, provides categorical funding to increase the capacity and capability of organizations that provide primary health care to provide HIV-related early

intervention services to medically underserved persons who have, or are at high risk for, HIV infection. These services are provided as part of a continuum of HIV prevention and health care services.

This clearance request is for extension of OMB approval of the Title III Program Data Report form, which is submitted annually by Title III grant recipients. The bulk of the information being collected describes the epidemiologic and demographic data on the populations receiving early intervention services from grant recipients, and

provides the basis for the annual report to the Secretary, which is legislatively mandated. It is also used to monitor the delivery of services, guide federal policy, and assist in program development and evaluation. Only minor revisions to the form are proposed, including deletion of some sections found to lack utility, revision of some data elements and instructions for clarity, and addition of data elements to improve the usefulness of the data.

The estimate of burden for the form is as follows:

Form name	No. of respondents	Responses per respondent	Hours per response	Total burden hours
Program Data Report Form	170	1	500	85,000

Send comments to Patricia Royston, HRSA Reports Clearance Officer, Room 14–36, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received within 60 days of this notice.

Dated: March 26, 1997.

#### J. Henry Montes,

Director, Office of Policy and Information Coordination.

[FR Doc. 97–8168 Filed 3–31–97; 8:45 am] BILLING CODE 4160–15–P

### The Ryan White Comprehensive AIDS Resources Emergency Act of 1990, as Amended by the Ryan White CARE Act Amendments of 1996

**AGENCY:** Health Resources and Services Administration, HHS.

**ACTION:** Notice of a Pre-Application Technical Assistance Workshop for Ryan White Title III HIV Planning Grants.

SUMMARY: The Health Resources and Services Administration (HRSA) will hold a pre-application technical assistance workshop for competing applicants for Ryan White Title III HIV Planning Grants, of Part C of Title XXVI of the Public Health Service (PHS) Act. A Ryan White Title III HIV Planning Grant will assist health care service entities to qualify for grant support under the Ryan White Title III Early Intervention Services Program.

Eligible applicants for the Ryan White Title III HIV Planning Grants are public or nonprofit private entities. Grant recipients of the Ryan White Title III Early Intervention Services Program are not eligible to receive Ryan White Title III HIV Planning Grants.

It should be noted that eligible applicants for the Ryan White Title III Early Intervention Services Program are public or private, nonprofit entities that are: Current primary care service providers to populations at risk for HIV disease; community health centers under section 330 of the PHS Act; migrant health centers under section 330(g) of the PHS Act; health care for the homeless grantees under section 330(h) of the PHS Act; family planning grantees under section 1001 of the PHS Act, other than states; comprehensive hemophilia diagnostic and treatment centers; or federally qualified health centers under section 1905(1)(2)(B) of the Social Security Act.

PURPOSE: The purpose of the preapplication technical assistance workshop is to provide information about the Ryan White Title III HIV Planning Grant program, and to review application procedures. Information will also be provided about the Ryan White Title III Early Intervention Services Program. Participants will have the opportunity to review the program guidance and to receive technical assistance pertaining to all aspects of writing a Ryan White Title III HIV Planning Grant application.

FOR FURTHER INFORMATION AND TO REGISTER: Anyone interested in attending this workshop must contact Ms. Karin Martinsen, Professional and Scientific Associates, Inc., 8180 Greensboro Drive, Suite 1050, McLean VA 22102–3823 (phone: 703–442–9824). Costs of attending the workshop are the sole responsibility of the attendee. There is a nominal registration fee of \$50 to cover the cost of materials, lunch and refreshments.

For general information, contact the HIV Primary Care Programs Branch,

Division of Programs for Special Populations, Bureau of Primary Health Care, 4350 East West Highway, Bethesda, MD 20814 (telephone: 301– 594–4444).

#### Date, Time, and Location

Wednesday, April 9, 1997 (the due date for the Ryan White Title III HIV Planning Grant is May 1, 1997). 10:00 a.m.–5:00 p.m., St. Louis Airport Marriot, St. Louis, Missouri, (314) 423–9700.

The OMB *Catalog of Federal Domestic Assistance* number for this program is 93.918.

Dated: March 26, 1997.

#### Claude Earl Fox,

Acting Administrator.

[FR Doc. 97–8167 Filed 3–31–97; 8:45 am]

BILLING CODE 4160-15-P

### National Institutes of Health

National Institute of Child Health and Human Development: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Development of a Microbial Screen for Anti-Virals Targeting PKR or Inhibitors of PKR

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

SUMMARY: The National Institutes of Health is seeking one or more CRADA partners for further development and evaluation of a microbial screen in yeast to identify anti-viral agents that target regulators of and/or the PKR kinase. The National Institute of Child Health and Human Development has established a system in yeast to identify and

characterize viral regulators of the PKR kinase, that should also be useful for identifying anti-viral agents that counteract the viral regulators. To expedite research and development of this system, the National Institutes of Health is seeking CRADAs with pharmaceutical or biotechnology companies in accordance with the regulations governing the transfer of Government-developed agents. Any proposal to use or develop this system will be considered.

ADDRESSES: CRADA proposals and questions about this opportunity should be addressed to: Dr. Gordon Guroff, Deputy Scientific Director, National Institute of Child Health and Human Development, Building 49, Room 5A64, Bethesda, MD 20892 (301/496–4751).

DATES: CRADA proposals should be received on or before July 30, 1997 for priority consideration. However, CRADA proposals submitted thereafter will be considered until a suitable CRADA Collaborator is selected.

SUPPLEMENTARY INFORMATION: The protein kinase PKR is a component of the interferon-induced anti-viral defense mechanism in mammalian cells. Upon activation by binding double-stranded RNA in infected cells, the kinase downregulates the cellular translational apparatus, and thus impairs viral protein expression. To overcome the inhibitory effects of PKR, viruses have developed efficient methods to prevent the activation or function of the kinase. A potential site of therapeutic intervention is to block viral inhibition of PKR.

The NICHD has developed a microbial system in the yeast Saccharomyces cerevisiae in which expression of PKR inhibits growth by down-regulating cellular protein synthesis. The toxicity of PKR in this system can be relieved by co-expression of viral regulatory factors including the vaccinia virus K3L protein. This simple microbial system should be amenable to high through-put screens to identify anti-viral agents that inactivate viral regulators of PKR, and thus restore PKR toxicity in this system. In addition, agents that act on PKR and reduce the sensitivity of PKR to viral regulatory factors could also be identified. This system should also be useful to identify regulators of PKR from other viruses, and then subsequently used to identify inhibitors of these newly identified viral regulatory factors.

In an effort to expedite research and development of new anti-viral agents targeting PKR, the National Institute of Child Health and Human Development seeks a CRADA partner(s) for joint

exploration. Any CRADA proposals for use of this system will be considered.

The CRADA aims will include the rapid publication of research results consistent with protection of proprietary information and patentable inventions as well as the timely exploitation of commercial opportunities. The CRADA partner will enjoy the benefits of first negotiation for licensing Government rights to any inventions arising under the agreement and will advance funds payable upon signing the CRADA to help defray Government expenses for patenting such inventions and other CRADA-related costs.

The role of the National Institute of Child Health and Human Development will be as follows:

- 1. Provide the collaborator with the data on the system covered by the agreement.
- 2. Provide the yeast strains and plasmids covered by the agreement.
- 3. Continue studies on the system to optimize growth tests for screens.
- 4. Work cooperatively with the Collaborator to perform the necessary controls to validate results from screens.
- 5. Jointly identify additional PKR inhibitors, and establish necessary strains for anti viral screens.

The role of the Collaborator will be as follows:

- 1. Undertake studies to evaluate the usefulness of this system for high through-put screens.
- 2. Cooperate to identify additional PKR inhibitors that could be tested using this system.
- 3. Undertake studies using this system to identify agents that inactivate viral inhibitors of PKR.

Selection criteria for choosing the CRADA Collaborator(s) will include but are not limited to the following:

1. The ability to collaborate with the NICHD on further research and development of this technology. This ability can be demonstrated through experience and expertise in this and related areas of technology.

2. The demonstration of adequate resources to perform the research and development of this technology (e.g., personnel, expertise, and facilities) and accomplish objectives according to an appropriate timetable to be outlined in the CRADA Collaborator's proposal.

3. The level of financial support the CRADA Collaborator will provide for CRADA related Government activities.

- 4. The willingness to cooperate with the NICHD in publication of research results consistent with the protection of proprietary information and patentable inventions which may arise during the period of the agreement.
- 5. Agreement to be bound by DHHS rules and regulations regarding human

subjects, patent rights, ethical treatment of animals, and randomized clinical trials.

6. Agreement with provisions for equitable distribution of patent rights to any inventions developed under the CRADA(s). Generally, the rights of ownership are retained by the organization which is the employer of the inventor, with an irrevocable, non-exclusive, royalty free license to the Government (when a company employee(s) is the sole inventor) or an option to negotiate an exclusive license to the company on terms that are appropriate (when the Government employee(s) are either sole or joint inventors).

Dated: March 18, 1997.

# Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97–8120 Filed 3–31–97; 8:45 am] BILLING CODE 4140–01–M

# DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4200-N-46]

# Notice of Proposed Information Collection for Public Comment

**AGENCY:** Office of the Assistant Secretary for Community Planning and Development, HUD.

**ACTION:** Proposed information collection for public comment.

SUMMARY: The proposed information collection requirement for the State Community Development Block Grant (CDBG) program will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: Comment due date: June 2, 1997.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Reports Liaison Officer, Shelia E. Jones, Department of Housing & Urban Development, 451 7th Street, SW, Room 7230, Washington, DC 20410–7000.

# FOR FURTHER INFORMATION CONTACT:

Steve Johnson, Acting Director, State and Small Cities Division, Department of Housing and Urban Development, Room 7286, 451 Seventh Street, SW, Washington, DC 20410–7000. For telephone communication, contact Yvette Aidara, State and Small Cities Division, at 202–708–1322. This is not